Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Other Non-Current Liabilities (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Other Non-Current Liabilities data on record, last reported at $11.0 million in Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 26.44% year-over-year to $11.0 million; the TTM value through Dec 2025 reached $11.0 million, up 26.44%, while the annual FY2025 figure was $11.0 million, 26.44% up from the prior year.
  • Other Non-Current Liabilities reached $11.0 million in Q4 2025 per ACRS's latest filing, up from $10.6 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $33.1 million in Q4 2022 and bottomed at $1.8 million in Q3 2023.
  • Average Other Non-Current Liabilities over 5 years is $12.2 million, with a median of $9.0 million recorded in 2024.
  • The widest YoY moves for Other Non-Current Liabilities: up 1487.22% in 2023, down 92.95% in 2023.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $28.4 million in 2021, then grew by 16.55% to $33.1 million in 2022, then tumbled by 81.27% to $6.2 million in 2023, then skyrocketed by 40.32% to $8.7 million in 2024, then increased by 26.44% to $11.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $11.0 million in Q4 2025, $10.6 million in Q3 2025, and $1.9 million in Q2 2025.